EMA Authorised: Comirnaty (single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2) — BioNTech Manufacturing GmbH

View source ↗

Summary

Comirnaty (BioNTech) has been authorised by the EMA for use in COVID-19, with the active substance being mRNA encoding the SARS-CoV-2 spike protein.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Virus Infection

Drugs mentioned

• Comirnaty (tozinameran)

Snippet

Status: Authorised. Therapeutic area: COVID-19 virus infection. MAH: BioNTech Manufacturing GmbH. Decision date: 08/04/2026